GlassScriptPhysician profile
Vladimir Privman
NPI 1659333193
$1,996.40
in general payments reported to CMS, 2019-2025
24 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $288 · 2021: $616 · 2022: $265 · 2023: $173 · 2024: $81.16 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $833.14 | 2019-2022 | |
| Abbvie INC. | $236.43 | 2020-2025 | |
| Lilly USA, LLC | $236.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amneal Pharmaceuticals LLC | $121.43 | 2022-2023 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.31 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $64.95 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Argenx US, INC. | $53.33 | 2022 | |
| Smith+Nephew, INC. | $40.14 | 2023 | Grafix Pl |
| Merck Sharp & Dohme LLC | $32.72 | 2020-2022 | |
| Boston Scientific Corporation | $26.67 | 2022 | |
| Csl Behring | $25.76 | 2021 | |
| Genzyme Corporation | $24.32 | 2019 | |
| Abbott Laboratories | $23.84 | 2021 | |
| Recor Medical INC | $23.04 | 2025 | Paradise Ultrasound Renal Denervation System |
| Medtronic, INC. | $21.11 | 2025 | Symplicity G3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.73 | 2025 | Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $18.92 | 2023 | Gvoke Hypopen |
| Beta Bionics, INC. | $17.87 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Vistapharm, INC. | $17.49 | 2021 | |
| Amryt Pharma Holdings LTD | $16.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.28 | 2019 | |
| Tandem Diabetes Care, INC. | $13.46 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eisai INC. | $11.90 | 2019 | |
| Allergan, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimir Privman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.